Diabetes research and clinical practice
-
Diabetes Res. Clin. Pract. · Mar 2013
Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance.
To detect plasma secreted frizzled-related protein (SFRP) 5 levels in Chinese healthy, obese and type 2 diabetes mellitus (T2DM) subjects and to investigate the relationships between plasma SFRP5 levels and body fat parameters, insulin resistance, glucolipid metabolism and inflammation. ⋯ Plasma levels of SFRP5 were decreased in Chinese obese and T2DM subjects. SFRP5 was an independent factor affecting glucolipid metabolism, inflammation and IR. It may play an important role in the pathogenesis of obesity and T2DM.
-
Diabetes Res. Clin. Pract. · Feb 2013
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone. Among a total of 663 patients identified to be taking pioglitazone, 9 had bladder cancer (1.36%). Overall the hazard ratio of 1.75 [95% CI: 0.89-3.45] for pioglitazone for bladder cancer was not significant. However the prevalence of bladder cancer was 2.10% in patients taking pioglitazone for less than 24 months which was significant increased (HR 2.73 [95% CI: 1.11-6.72]).
-
Diabetes Res. Clin. Pract. · Jan 2013
Intraepidermal nerve fiber density and nerve conduction study parameters correlate with clinical staging of diabetic polyneuropathy.
To assess the usefulness of the diagnostic and staging criteria for diabetic polyneuropathy (DP) by the Diabetic Neuropathy Study Group in Japan (DNSGJ) we examined clinical features, intraepidermal nerve fiber densities (IENFD) and nerve conduction studies (NCS) and coefficient of variation of the R-R intervals (CVR-R) in 44 patients with diabetes. ⋯ Clinical staging for DP by DNSGJ reflects the results of small and large fiber neuropathy.
-
Diabetes Res. Clin. Pract. · Dec 2012
Randomized Controlled Trial Comparative StudyMetformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
To evaluate the effect of metformin and insulin in glycemic control and compare pregnancy outcome in women with gestational diabetes mellitus (GDM). ⋯ Metformin is an effective and safe alternative treatment to insulin for women with GDM. This study does not show significant risk of maternal or neonatal adverse outcome with the use of metformin.